Walleye Capital’s Ginkgo Bioworks DNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$21.8K Sell
1,700
-8,500
-83% -$69.3K ﹤0.01% 5636
2026
Q2
$101K Buy
+10,200
New +$85.3K ﹤0.01% 3897
2026
Q1
– Sell
-4,100
Closed -$34.1K – 4522
2025
Q4
$34.1K Sell
4,100
-4,300
-51% -$46.3K ﹤0.01% 4160
2025
Q3
$122K Buy
+8,400
New +$101K ﹤0.01% 3612
2025
Q1
– Sell
-14,100
Closed -$138K – 4419
2024
Q4
$138K Buy
14,100
+2,800
+25% +$24K ﹤0.01% 3966
2024
Q3
$92.1K Buy
+11,300
New +$113K ﹤0.01% 4424

Other funds holding DNA

Walleye Capital's DNA Position: Q3 2026 in Review

Walleye Capital increased its Ginkgo Bioworks (DNA) stake by 729% in Q3 2026, buying an estimated $1.13M and bringing the position to 158,116 shares worth $2.03M. The position accounts for ﹤0.01% of the portfolio, ranked #2805.

Walleye Capital first reported a position in DNA in Q3 2024 and has held it in 5 quarters since. The position peaked at $2.61M in Q4 2024. 185 funds tracked by Wall St. Rank hold DNA as of Q3 2026.

  • Walleye Capital held 158,116 shares of Ginkgo Bioworks worth $2.03M as of Q3 2026.
  • Walleye Capital bought 139,050 Ginkgo Bioworks shares in Q3 2026, an estimated $1.13M.
  • Ginkgo Bioworks made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #2805 holding.
  • Walleye Capital first reported a position in Ginkgo Bioworks in Q3 2024 and has held it in 5 quarters since.
  • Walleye Capital's Ginkgo Bioworks position peaked at $2.61M in Q4 2024.
  • 185 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.